| Description | Girisopam is a novel selective benzodiazepine analog for the 2,3-benzodiazepine binding site, an atypical psychoanalytic with anxiolytic effects. |
| In vivo | Girisopam（100 mg；口服；男性受试者）服用后20分钟，迅速吸收。Girisopam平均2.0小时时达到178 ng/ml的平均血清水平，随后其血清浓度开始下降，平均消除半衰期为22.2小时。[1] |
| molecular weight | 328.79 |
| Molecular formula | C18H17ClN2O2 |
| CAS | 82230-53-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 4.23 mg/mL (12.87 mM), Sonication is recommended. |
| References | 1. Tomori E, et al. Pharmacokinetic and metabolism studies on girisopam by chromatographic and spectrometric methods in humans. J Chromatogr. 1992;578(1):91-101. 2. Dereszlay I, et al. Study of the bone marrow penetration of radioactivity after oral administration of radiolabelled girisopam (EGIS-5810) in mice. Acta Physiol Hung. 1997;85(2):139-148. 3. Horváth K, et al. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone. Acta Physiol Hung. 1992;79(2):153-161. 4. Horváth EJ, et al. Changes in specific binding sites of girisopam after chemical and surgical lesions in the striato-nigral system. Brain Res Mol Brain Res. 1997;45(1):141-14 |